- Haemoglobin (HGB)
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Adverse effects observed in trials include: Nausea and vomiting particularly during dose escalation Diarrhoea or constipation Decreased appetite Injection site reactions Fatigue and dizziness Gallbladder-related events (including gallstones), consistent with effects observed with other GLP-1based therapies [9] Rare cases of pancreatitis , a risk associated with the GLP-1 receptor agonist class [10] [3] Because retatrutide is not licensed in the UK, the MHRA has not issued specific prescribing or dosing guidance for this compound
The Substance (or Lack Thereof) Despite high-tech packaging and persuasive visuals, several areas stand out: LBM LBM GLP 1 Nano Microneedle Patch uses words like LBM LBM, Nano Microneedle, and Semaglutide, indicating it delivers an oral drug-like treatment through patch technology
In some people, however, these medications can also cause unpleasant-to-severe bouts of vomiting, which may require medical attention
Clinicians should treat adherence to GLP-1 treatment as an important outcome in its own right not an afterthought, Al-Aly said
